ERICA: prevalência de asma em adolescentes brasileiros

OBJETIVO Descrever a prevalência de asma ativa e de diagnóstico médico de asma em adolescentes brasileiros. MÉTODOS Estudo transversal, nacional, de base escolar com adolescentes de 12 a 17 anos, participantes do Estudo de Riscos Cardiovasculares em adolescentes (ERICA). A amostra foi estratificada por região e conglomerada por escolas e turmas com representatividade para o conjunto de municípios com mais de 100 mil habitantes do País, macrorregiões, capitais e Distrito Federal. Os dados foram coletados em questionário autopreenchível. Foram calculadas as prevalências e respectivos intervalos de confiança de 95% (IC95%) segundo sexo, faixa etária, tipo de escola e cor da pele. RESULTADOS Entre 2013 e 2014 foram avaliados 74.589 adolescentes, 55,3% do sexo feminino. A prevalência total de asma ativa foi 13,1% (IC95% 12,1-13,9), sendo superior nas meninas (14,8%; IC95% 13,7-16,0) em relação aos meninos (11,2%; IC95% 10,3-12,2) em todos estratos geográficos analisados, e também entre os alunos da rede privada (15,9%; IC95% 14,2-17,7) em relação aos de escolas públicas (12,4%; IC95% 11,4-13,4). Foi mais elevada na região Sudeste (14,5%; IC95% 12,9-16,1) e na cidade de São Paulo (16,7%; IC95% 14,7-18,7). A menor prevalência foi observada na região Norte (9,7%; IC95% 9,7-10,5) e em Teresina (6,3%; IC95% 4,9-7,7). A prevalência de diagnóstico médico de asma foi 8,7% (IC95% 8,2-9,1); mais elevada na região Norte (13,5%; IC95% 12,7-14,2) e em Porto Alegre (19,8%; IC95% 17,5-22,3) e mais baixa no Centro-Oeste (6,9%; IC95% 6,0-7,8) e em Cuiabá (4,8%; IC95% 3,8-5,9). Não ocorreu diferença significativa na expressão desta taxa entre os sexos, assim como nas outras variáveis avaliadas pelo estudo. CONCLUSÕES A prevalência de asma em adolescentes brasileiros é alta. As taxas de asma ativa e de diagnóstico médico variam amplamente nas diferentes regiões e capitais avaliadas pelo ERICA. Estes resultados poderão auxiliar na elaboração de programas preventivos e de políticas de saúde e no melhor entendimento sobre os fatores associados à asma nessa faixa etária.OBJECTIVE To describe the prevalence of asthma and physician-diagnosed asthma in Brazilian adolescents. METHODS Cross-sectional, national, school-based study with adolescents from 12 to 17 years old, participants in the Study of Cardiovascular Risks in Adolescents (ERICA). The study stratified the sample by region and grouped according to schools and classes with representativeness to the set of cities with more than 100,000 inhabitants of the Country, macro-regions, capitals, and Federal District. A questionnaire collected data through a self-filled in method. We calculated the prevalences and their confidence intervals of 95% (95%CI) according to sex, age group, type of school and skin color. RESULTS Between 2013 and 2014, 74,589 adolescents were evaluated, 55.3% of the female sex. The total prevalence of active asthma was of 13.1% (95%CI 12.1-13.9), being higher in girls (14.8%; 95%CI 13.7-16.0) when compared to boys (11.2%; 95%CI 10.3-12.2) in all geographical strata examined. It was also higher between students of private schools (15.9%; 95%CI 14.2-17.7) when compared to public ones (12.4%; 95%CI 11.4-13.4). It was higher in the Southeast region (14.5%; 95%CI 12.9-16.1), and in the city of Sao Paulo (16.7%; 95%CI 14.7-18.7). The lowest prevalence was observed in North region (9.7%; 95%CI 9.7-10.5), and in Teresina (6.3%; 95%CI 4.9-7.7). The prevalence of physician-diagnosed asthma was of 8.7% (95%CI 8.2-9.1); higher in the North region (13.5%; 95%CI 12.7-14.2), and in Porto Alegre (19.8%; 95%CI 17.5-22.3). It was lower in the Midwest (6.9%; 95%CI 6.0-7.8), and in Cuiaba (4.8%; 95%CI 3.8-5.9). We found no significant difference in the expression of this rate between the sexes, as well as in other variables evaluated by the study. CONCLUSIONS The prevalence of asthma in Brazilian adolescents is high. Rates of active asthma and physician-diagnosed asthma vary widely in different regions and capitals evaluated by the ERICA. These results may assist in the preparation of preventive programs and policies on health and a better understanding of the factors associated with asthma in this age group

ERICA: prevalence of asthma in Brazilian adolescents

OBJECTIVE: To describe the prevalence of asthma and physician-diagnosed asthma in Brazilian adolescents. METHODS: Cross-sectional, national, school-based study with adolescents from 12 to 17 years old, participants in the Study of Cardiovascular Risks in Adolescents (ERICA). The study stratified the sample by region and grouped according to schools and classes with representativeness to the set of cities with more than 100,000 inhabitants of the Country, macro-regions, capitals, and Federal District. A questionnaire collected data through a self-filled in method. We calculated the prevalences and their confidence intervals of 95% (95% CI) according to sex, age group, type of school and skin color. RESULTS: Between 2013 and 2014, 74,589 adolescents were evaluated, 55.3% of the female sex. The total prevalence of active asthma was of 13.1% (95% CI 12.1-13.9), being higher in girls (14.8%; 95% CI 13.7-16.0) when compared to boys (11.2%; 95% CI 10.3-12.2) in all geographical strata examined. It was also higher between students of private schools (15.9%; 95% CI 14.2-17.7) when compared to public ones (12.4%; 95% CI 11.4-13.4). It was higher in the Southeast region (14.5%; 95% CI 12.9-16.1), and in the city of Sao Paulo (16.7%; 95% CI 14.7-18.7). The lowest prevalence was observed in North region (9.7%; 95% CI 9.7-10.5), and in Teresina (6.3%; 95% CI 4.9-7.7). The prevalence of physician-diagnosed asthma was of 8.7% (95% CI 8.2-9.1); higher in the North region (13.5%; 95% CI 12.7-14.2), and in Porto Alegre (19.8%; 95% CI 17.5-22.3). It was lower in the Midwest (6.9%; 95% CI 6.0-7.8), and in Cuiaba (4.8%; 95% CI 3.8-5.9). We found no significant difference in the expression of this rate between the sexes, as well as in other variables evaluated by the study. CONCLUSIONS: The prevalence of asthma in Brazilian adolescents is high. Rates of active asthma and physician-diagnosed asthma vary widely in different regions and capitals evaluated by the ERICA. These results may assist in the preparation of preventive programs and policies on health and a better understanding of the factors associated with asthma in this age group.Department of Science and Technology of the Science, Technology and Strategic Inputs Secretariat from the Brazilian Ministry of Health (Decit/SCTIE/MS)Health Sector Fund (CT-Saude) of the Ministry of Science, Technology and Innovation (MCTI)Research Incentive Fund of the Hospital de Clinicas de Porto AlegreUniv Estado Rio de Janeiro, Fac Ciencias Med, Dept Pediat, BR-20550011 Rio De Janeiro, RJ, BrazilUniv Fed Sergipe, Dept Med, Aracaju, SE, BrazilUniv Fed Sao Paulo, Dept Pediat, Disciplina Alergia Imunol Clin & Reumatol, Sao Paulo, SP, BrazilUniv Estado Rio de Janeiro, Fac Ciencias Med, Dept Med Interna, BR-20550011 Rio De Janeiro, RJ, BrazilUniv Estado Rio de Janeiro, Fac Ciencias Med, Programa Posgrad Ciencias Med, BR-20550011 Rio De Janeiro, RJ, BrazilUniv Estado Rio de Janeiro, Inst Nutr, Dept Nutr Aplicada, BR-20550011 Rio De Janeiro, RJ, BrazilFundacao Inst Brasileiro Geog & Estat, Escola Nacl Ciencias Estat, Rio De Janeiro, RJ, BrazilUniv Estado Rio de Janeiro, Fac Ciencias Med, Nucleo Estudos Saude Adolescente, BR-20550011 Rio De Janeiro, RJ, BrazilUniv Fed Sao Paulo, Dept Pediat, Disciplina Alergia Imunol Clin & Reumatol, Sao Paulo, SP, BrazilMCTI: FINEP - 01090421CNPq: 565037/2010-2Research Incentive Fund of the Hospital de Clinicas de Porto Alegre FIPE-HCPA: 405.009/2012-7Web of Scienc

Drug-induced anaphylaxis, elicitors, risk factors, and management in Latin America

Nonsteroidal anti-inflammatory drugs were the most frequent triggers of drug-induced anaphylaxis in Latín America, whereas antibiotics elicited faster onset and more scvere reactions. An improvement was observed in epinephrinc use and adherence to guidelines in the emergency department treatment of anaphylaxis in Latín America compared with our last report.Facultad de Ciencias Médica

Desensitization to drugs in children

Better knowledge and understanding about drug desensitization is required in the pediatric population, since there is little literature available about it and the most pediatric desensitization protocols have been adapted from adult instructions.Aiming to soften this issue and foster the future studies, this article presents a recent review about mechanisms of desensitization, diagnostic tools, and up to date management of drug hypersensitivity reactions in children. Bringing up an overview of pediatric hypersensitivity reactions to chemotherapy, biologic agents, antibiotics, nonsteroidal anti-inflammatory drugs, and vaccines

Physician practices and attitudes towards atopic dermatitis in Latin America: A cross-sectional study

Background: The prevalence of atopic dermatitis (AD) is increasing in developing countries. Different worldwide guidelines have been proposed, but their applicability for AD specialists in Latin American (LA) countries is unknown. Objective: The objective of this study was to explore the medical approach to treating AD in LA countries. Methods: The study population comprised AD specialists (allergists and dermatologists). They completed an electronic survey containing questions about the health system, diagnostic criteria, and pharmacotherapy approach to treating AD. The survey was constructed and validated by the Atopic Dermatitis Committee of the Latin American Society of Allergy Asthma and Immunology (SLAAI) in Spanish and Portuguese. Each member was responsible for distributing the questionnaire through different networks in their respective countries. Results: A total of 284 AD specialists from 13 LA countries completed the questionnaire; among them, 67% were allergists and 33% were dermatologists. Less than 50% of the AD specialists strictly followed guideline recommendations. Among the AD specialists, the European and North American guidelines were more frequently used, and only 16% followed LA guidelines. Dermatologists used the local guidelines less frequently than allergists. Most physicians did not routinely use AD assessment tools (55%). The frequency of the diagnostic tests depends on symptom severity. The availability of some systemic treatments, such as biologics and Janus Kinase (JAK) inhibitors, is not universal in all LA countries. Conclusion: There were marked differences between the specialists, and these differences seemed to be affected by their specialty and each country's healthcare system. New AD education strategies that consider the particularities of the region could allow patients to be more accurately managed. AD assessment tools may provide a way to enhance AD treatment and allow for shared decision-making, patient empowerment, and standardized care

A concept for integrated care pathways for atopic dermatitis—A GA2LEN ADCARE initiative

Abstract Introduction The integrated care pathways for atopic dermatitis (AD‐ICPs) aim to bridge the gap between existing AD treatment evidence‐based guidelines and expert opinion based on daily practice by offering a structured multidisciplinary plan for patient management of AD. ICPs have the potential to enhance guideline recommendations by combining interventions and aspects from different guidelines, integrating quality assurance, and describing co‐ordination of care. Most importantly, patients can enter the ICPs at any level depending on AD severity, resources available in their country, and economic factors such as differences in insurance reimbursement systems. Methods The GA2LEN ADCARE network and partners as well as all stakeholders, abbreviated as the AD‐ICPs working group, were involved in the discussion and preparation of the AD ICPs during a series of subgroup workshops and meetings in years 2020 and 2021, after which the document was circulated within all GAL2EN ADCARE centres. Results The AD‐ICPs outline the diagnostic procedures, possible co‐morbidities, different available treatment options including differential approaches for the pediatric population, and the role of the pharmacists and other stakeholders, as well as remaining unmet needs in the management of AD. Conclusion The AD‐ICPs provide a multidisciplinary plan for improved diagnosis, treatment, and patient feedback in AD management, as well as addressing critical unmet needs, including improved access to care, training specialists, implementation of educational programs, assessment on the impact of climate change, and fostering a personalised treatment approach. By focusing on these key areas, the initiative aims to pave the way for a brighter future in the management of AD